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ORIGINAL ARTICLE
Methylphenidate and the risk of psychotic disorders and
hallucinations in children and adolescents in a large
health system
KKC Man1,2,11, D Coghill3,4,11, EW Chan1, WCY Lau1, C Hollis5,6,11, E Liddle5,6,11, T Banaschewski7,11, S McCarthy8,11, A Neubert9,11,
K Sayal5,6,11, P Ip2 and ICK Wong1,10,11
Previous studies have suggested that risk of psychotic events may be increased in children exposed to methylphenidate (MPH).
However, this risk has not been fully examined, and the possibility of confounding factors has not been excluded. Patients aged 6–
19 years who received at least one MPH prescription were identiﬁed using Hong Kong population-based electronic medical records
on the Clinical Data Analysis and Reporting System (2001–2014). Using the self-controlled case series design, relative incidence of
psychotic events was calculated comparing periods when patients were exposed to MPH with non-exposed periods. Of 20,586
patients prescribed MPH, 103 had an incident psychotic event; 72 (69.9%) were male and 31 (30.1%) female. The mean age at
commencement of observation was 6.95 years and the mean follow-up per participant was 10.16 years. On average, each
participant was exposed to MPH for 2.17 years. The overall incidence of psychotic events during the MPH exposure period was 6.14
per 10,000 patient-years. No increased risk was found during MPH-exposed compared with non-exposed periods (incidence rate
ratio (IRR) 1.02 (0.53–1.97)). However, an increased risk was found during the pre-exposure period (IRR 4.64 (2.17–9.92)). Results
were consistent across all sensitivity analyses. This study does not support the hypothesis that MPH increases risk of incident
psychotic events. It does indicate an increased risk of psychotic events before the ﬁrst prescription of MPH, which may be because
of an association between psychotic events and the behavioural and attentional symptoms that led to psychiatric assessment and
initiation of MPH treatment.
Translational Psychiatry (2016) 6, e956; doi:10.1038/tp.2016.216; published online 15 November 2016
INTRODUCTION
Attention deﬁcit/hyperactivity disorder (ADHD) is a common
neurodevelopmental disorder characterised by a persistent
pattern of inattention, hyperactivity and impulsivity that is per-
vasive across different settings.1 It is common among school-aged
children and adolescents with a worldwide prevalence around
5%.2 ADHD has a diverse range of adverse outcomes in health,
intellectual and psychosocial well-being.3 Children with ADHD
frequently experience low academic attainment, rejection by
peers and low self-esteem.4 In addition, ADHD is frequently
comorbid with other mental health problems such as conduct
disorders and substance misuse.5–7 Therefore, behavioural inter-
vention and/or drug treatment is usually required to mitigate
these symptoms and impairments. The guidelines from the
National Institute for Health and Clinical Excellence (NICE) in the
United Kingdom recommend the use of methylphenidate (MPH),
dexamfetamine and atomoxetine when drug intervention is
considered appropriate for the management of ADHD.8 In the
past two decades, ADHD treatment prescribing trends have risen
rapidly in the United States (US),9 Canada,10 the UK,11,12 Germany13
and Hong Kong (HK).14 As suggested by a very recently published
commentary and a meta-analysis, it is important to evaluate the
risks (that is, adverse effects) as well as beneﬁts of MPH treatment
in clinical practice.15,16
MPH is the most commonly prescribed medication treatment
for ADHD.11,14 It acts primarily as a dopamine–norepinephrine
reuptake inhibitor by binding to and blocking dopamine
transporters.17 As increased levels of synaptic dopamine are
implicated in the generation of psychotic symptoms,18 the
pharmacological mechanism of MPH also implies a potential to
induce psychotic symptoms and disorders.19 Data from the UK
Medicines and Healthcare Products Agency’s Yellow Card scheme20
showed that out of 1335 adverse drug reaction (ADR) reports for
MPH received by the end of July 2015, 663 were associated with
psychiatric disorders, making these the most frequently reported
class of ADR. Among these reports, 105 cases (15.8%) reported
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hallucinations, psychosis or psychotic disorders, or schizoaffective
disorders. Mosholder et al.21 reviewed and analysed data from the
medication manufacturers on ADHD drugs from 49 randomised
controlled clinical trials. They identiﬁed a total of 11 psychosis/
mania adverse events during 743 person-years of follow-up in
5717 individuals (1.48 events per 100 person-years or one event in
every 70 years of treatment) compared with none reported with
placebo, giving a number needed to harm of 526.
These reports raise the possibility that MPH treatment may be
associated with an increased risk of psychosis or related events. In
2007, the European Commission requested a referral to the
Committee for Medicinal Products for Human Use under Article 31
of Directive 2001/83/EC, as amended, for MPH because of safety
concerns.22,23 One of the main potential safety areas that was
evaluated concerned adverse psychiatric events including psy-
chosis. In 2009, the Committee for Medicinal Products for Human
Use concluded that the beneﬁt-risk of MPH remains favourable in
the authorised indication, but that further research on safety is
needed.23 In view of the dopamine agonist effect of MPH, the
observed reports of an association between MPH and hallucina-
tions, psychosis or psychotic disorders (collectively described here
as 'psychotic events')17 and increasing use of MPH worldwide,
there is a clear need for a systematic investigation into the
association between MPH and psychotic events. One recent study
has investigated the relationship between ADHD and schizo-
phrenia spectrum disorders.24 Although the authors found an
increased risk of psychotic disorder in MPH users, they recognised
that several important pieces of potentially confounding clinical
information were not available to the study team. These included
the following: the severity of ADHD symptoms; family history of
psychosis; and history of substance misuse. Thus, it is not possible
to determine whether the ﬁnding of a positive association between
MPH treatment and psychosis in this analysis was in fact a con-
sequence of confounding by other important differences between
MPH-treated patients and the control group that themselves
increase the likelihood of receiving MPH treatment.24
The aim of this study was to address these shortcomings by
examining the association between MPH and the risk of psychotic
events using the self-controlled case series (SCCS) method. With
this method, cases act as their own controls and observations are
made within cases over time. In this study, comparisons were
made within a clinically referred sample of individuals with
psychotic events who have been prescribed MPH in the setting of
a territory-wide hospital database in HK. We hypothesised that
MPH treatment will be associated with increased incidence of
psychotic events following MPH exposure.
MATERIALS AND METHODS
The Clinical Data Analysis And Reporting System
This study was conducted using the Clinical Data Analysis and Reporting
System (CDARS), an electronic health record database developed by the
Hong Kong Hospital Authority (HA), a statutory body that manages all
public hospitals and their ambulatory clinics in HK. The service is available
to all HK residents (over 7 million) and covers ~ 80% of all hospital
admissions in HK.25 Data from CDARS have proved to be reliable for use in
research and have been used for various pharmacoepidemiological
studies.25–29 These have included MPH investigation of prescribing trends
in HK, and of the association between MPH treatment and risk of
trauma.14,30 CDARS has also been used to investigate psychiatric and
neurological ADRs.31,32 Patient-speciﬁc clinical data in CDARS include
diagnosis, prescription, and information on admission and discharge, all of
which are recorded by trained clinicians. Other patient-speciﬁc data such
as demographics, payment method, prescription and pharmacy-
dispensing information are entered by other trained staff.33 CDARS
contains the records of all in-patient, out-patient and emergency room
admissions in HA clinics and hospitals since 1995. Records are anonymised
to protect patient conﬁdentiality. Unique patient reference numbers are
generated to facilitate data retrieval. Detailed descriptions of CDARS can
be found elsewhere.14,34 Previous validation studies have shown high
positive predictive values for various medical diagnoses.25,28
SCCS design
The SCCS35 study design was speciﬁcally selected to investigate the
association between MPH and psychosis. This method has been used
previously to investigate the effects of MPH on emergency room admission
in HK.30 In SCCS, each patient serves as their own control and the
modelling is conditional in that all cases will have experienced the
outcome of interest at some stage during the study window.36 This study
design relies on within-person comparisons in a population of individuals
who have experienced both the outcome and exposure of interest.36
Incidence rate ratios (IRRs) are derived by comparing the rate of events
during exposed periods (on medication) with the rate during all other
observed time periods (off medication). A major advantage of this design is
that the potential time-invariant confounding effect of ﬁxed characteristics
(both recorded and unrecorded) that vary between individuals and may
underlie disease severity, such as genetic and socioeconomic factors, are
removed. The underlying risks of psychotic events among MPH users and
non-users are likely to be different because of factors relating to ADHD and
its comorbidities, and are difﬁcult to control for in most observational
study designs. This can be a major issue in cohort or case–control studies
as the comparison group may not be appropriately selected. The SCCS
design, in which confounding between individuals is controlled implicitly,
is able to address these factors that may not be controlled in classic
epidemiological study designs. Furthermore, we are able to adjust for
factors that vary with time, particularly age and seasonal effects, as both
the MPH treatment prescribing and psychiatry visits have age and seasonal
patterns.37,38
Case identiﬁcation
Individuals aged 6–19 years who received at least one prescription of MPH
with at least one psychotic disorder and/or hallucination diagnostic code
(psychotic events) during the study period (January 2001 to December
2014) were identiﬁed in CDARS. The psychotic event codes were identiﬁed
through the diagnostic codes from the International Classiﬁcation of
Diseases, Ninth Revision, Clinical Modiﬁcation (ICD-9-CM). Patients with
psychotic events before the start of follow-up were excluded. The included
diagnosis codes are listed in Supplementary Table 1. Only MPH and
atomoxetine are licensed for the treatment of ADHD in HK; therefore, the
observation periods were censored by atomoxetine treatment to avoid a
co-prescribing situation, which may affect comparisons. In HK, ~ 5% of
treated ADHD patients received both MPH and atomoxetine.14 Individual
observation periods commenced on January 2001, or the sixth birthday of
the patient (whichever was later), and ended on December 2014, the
twentieth birthday of the patient, date of receiving atomoxetine treatment
or the date of registered death (whichever was earlier). We commenced
follow-up at 6 years of age because MPH is not recommended for younger
children.39 As the aim of this pharmacovigilance study is to investigate the
association between MPH and incident psychotic events, a diagnosis of
ADHD was not an inclusion criterion.
Exposures and outcomes
For each included participant, records of all MPH prescriptions and
psychotic events were identiﬁed. All formulations of MPH (standard and
extended release) and all strengths were included in the analysis. ‘Exposed
periods’ were deﬁned as time on-medication and were estimated by the
duration between prescription start and end date recorded in CDARS for
each prescription. Over 99% of prescriptions have the intended start and
end date of the treatment recorded in our data set. Daily dosages and
quantity prescribed were used to determine the duration of treatment if
prescription end date was not available. The median values for exposure
duration were imputed when the above information was missing. Periods
within the observation period other than exposure periods were classiﬁed
as baseline periods. We did not assume that participants received
continuous treatment upon initiation of MPH. This is because clinicians
may offer drug holidays to ADHD patients during school holidays, and
treatment may be stopped and started for various reasons. A pictorial
presentation of the study design and timeline for a single hypothetical
participant is given in Figure 1. Psychotic events were identiﬁed through
ICD-9-CM codes (Supplementary Table 1) by CH and KS. The corresponding
date of a psychotic event was identiﬁed by the event date and only the
incident psychotic event for each patient was included in the analysis. We
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conducted a validation analysis by reviewing the information in CDARS.
Through this we identiﬁed that in 98 out of 103 (95.1%) cases the diagnosis
of a psychotic event was conﬁrmed by a hospital paediatrician and/or
psychiatrist. All included patients were under the care of specialist clinics
managing childhood mental health conditions. Consequently, the risk of
misdiagnosis is considered to be low.
Statistical analysis
The primary analysis investigated the relationship between MPH treatment
and the occurrence of incident psychotic events. This was calculated by
comparing the rate of psychotic events during exposed periods to that
during baseline periods. Adjusted IRR and the corresponding 95%
conﬁdence intervals (CIs) were calculated using conditional Poisson
regression, adjusting for age, in 1-year bands, and season. As the psychotic
event itself may potentially have an impact on the likelihood of receiving
MPH treatment, which in turn may introduce bias into the risk estimate
during treatment, a 90-day pre-exposure period was added to remove the
short-term impact of this effect (Figure 1). For a psychotic event that
occurred on day 1 of MPH treatment, we reviewed the temporal
relationship of this event and treatment, that is, whether it was before
or after initiation of MPH. If an event occurred before the MPH treatment
was prescribed, it would be classiﬁed as pre-exposure period instead of
day 1. A signiﬁcance level of 5% was used in all statistical analyses.
Microsoft Excel and Statistical Analysis System (SAS) v9.3 (SAS Institute,
Cary, NC, USA) were used for data manipulation and analysis.
Code availability
Analysis codes are available upon request to the corresponding author.
Sample size calculation
Using the approach and equation suggested by Musonda et al.,40 an IRR of
2 with 80% power (two-sided 95% CI) could be detected with a minimum
of 76 psychosis cases.
Sensitivity analyses
Several sensitivity analyses were planned to test the validity and
robustness of the initial study results: (1) Alternative analyses were
conducted based on different drug non-adherence scenarios. Each
exposed period was further extended by adding 1–10 weeks after the
end of an exposed period to assess this effect. (2) To assess the sensitivity
of age-banding used, an analysis with a 6-month age band rather than
annual bands was conducted. (3) Additional analyses were conducted on a
subset of patients with more than 10 weeks of MPH exposure in order to
test the effects of more prolonged medication exposure. (4) Patients with a
diagnosis of substance misuse/dependence (ICD-9-CM: 303-305) were
removed from the analysis. (5) The individual observation period was
censored by the date of prescription of any antidepressant or antipsychotic
medications during the study period. (6) The outcome was restricted to
ICD-9-CM psychotic disorders only meaning that those with hallucinations
(ICD-9-CM: 780.1) were removed from the analysis. (7) Cases where the
event occurred on the ﬁrst day of prescription were removed. (8) Different
washout periods (7–21 days) were implemented before the initiation of
MPH treatment and these periods were excluded from the analysis. (9) The
observation period was started at January 2001, the sixth birthday of the
patient, the ﬁrst observed date of ADHD diagnosis or the ﬁrst date of MPH
treatment, whichever occurred later. (10) Different lengths of pre-exposure
period (30 and 60 days) were used.
Ethical approval
This study protocol was approved by the Institutional Review Board of the
University of Hong Kong/Hospital Authority Hong Kong West Cluster
(Reference Number: UW12-136).
RESULTS
Among 20,586 patients with MPH prescriptions, 103 were included
in the primary analysis (Figure 2), of which 72 (69.9%) were male
and 31 (30.1%) were female. The mean age at commencement of
observation was 6.95 years and the mean duration of follow-up
per participant was 10.16 years. The mean exposure to MPH was
2.17 years per participant. The median length of each prescription
was 70 days. In all, 76 out of 103 patients had a clinical ADHD
diagnosis and the median age of diagnosis was 9.5 years
Figure 1. Illustration of the self-controlled case series study design.
Figure 2. Flowchart of patient identiﬁcation. ADHD, attention
deﬁcit/hyperactivity disorder.
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(interquartile range 8.2–11.7). There were 103 incident psychotic
events, of which 78 occurred during baseline periods and 25
occurred during the MPH treatment period (Table 1). Among the
103 cases, 80 were psychosis cases (ICD-9-CM: 298.0, 298.1, 298.3,
298.8, 298.9), 20 were hallucinations (ICD-9-CM: 780.1) and 3 were
other psychotic disorders (other codes in Supplementary Table 1).
The overall incidence of psychotic events during the MPH
treatment period was 6.14 per 10,000 patient-years. No partici-
pants died during the study period. Broader psychiatric comor-
bidities for these patients are shown in Table 2.
The primary analysis indicated no statistically signiﬁcant
association between MPH treatment and occurrence of incident
psychotic events (Table 3). After adjusting for age and season, the
IRR was 0.98 (95% CI 0.52–1.86). After including a 90-day pre-
exposure period, a similar result was found with an IRR during
treatment of 1.02 (95% CI 0.53–1.97). Compared with the baseline,
an IRR of 4.64 (95% CI 2.17–9.92) was found in the 90-day pre-MPH
treatment period (Table 3). Direct comparison between the risk of
psychotic events during the MPH treatment period and the
pre-exposure period showed that the corresponding risk during
MPH treatment period is lower than during the pre-exposure
period (IRR = 0.13; 95% CI 0.04–0.50; P-value 0.003). The additional
sensitivity analyses all gave similar results (Table 3 and
Supplementary Figure 1).
DISCUSSION
These data do not support the presence of an association
between the use of MPH and the development of incident
psychotic events (IRR = 1.02 (95% CI 0.53–1.97)). However, a
positive IRR was observed in the pre-MPH treatment periods
(IRR = 4.64, 95% CI 2.17–9.92), which was markedly elevated
relative to the risk of incident psychotic events during MPH
treatment.
Possible reasons for an increased risk of incident psychotic
events before starting MPH treatment include the co-occurrence
of transient psychotic events with ADHD, or with clinical contact
and observation in the period leading up to initiation of MPH. It is
well recognised that patients with ADHD are prone to cognitive,
emotional and behavioural comorbidities.7 These comorbidities
may increase the likelihood of psychiatric consultation, which may
consequently increase both the chance of incident psychotic
events being identiﬁed and being prescribed MPH. This increased
diagnosis of incident psychotic events in the period before the
ﬁrst ever MPH treatment may also explain the ADR reports of
psychiatric adverse events for MPH, as cited in the literature.41–45
If, as our evidence suggests, the diagnosis of incident psychotic
events is higher before the MPH treatment, this may increase theT
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Table 2. Psychiatric comorbidities of patients with psychotic events
ICD-9-CM Number of
patients
%
Acute reaction to stress 308 22 21.4
Adjustment disorder 309 12 11.7
Anxiety disorder 293.84, 300 11 10.7
Autism spectrum disorder 299 22 21.4
Disturbance of conduct not
elsewhere classiﬁed
312 25 24.3
Speciﬁc delays in development 315 16 15.5
Other psychiatric comorbiditiesa 290–319 73 70.9
Abbreviation: ICD-9-CM, International Classiﬁcation of Diseases, Ninth
Revision, Clinical Modiﬁcation. aOther psychiatric comorbidities included
all other disorders from ICD-9-CM code 290–319 that were not psychosis or
listed above.
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likelihood of subsequent diagnosis of recurrent psychotic events,
and thus reports of psychotic events associated with MPH
treatment in clinical practice.
Several case reports of MPH-induced psychosis-like symptoms
in children have been published.41,42,44,45 However, most of these
patients also had other psychiatric conditions such as emotional
and behavioural disorders. Therefore, it is important to note that
these reported psychotic events may not be induced by ADHD
medication but could simply reﬂect the deterioration of a
coexisting psychiatric disorder. In addition, the important ﬁnding
reported here of an increased risk of psychotic events' pretreat-
ment may not be observed in a classic cohort study, where
patients with either events or exposures before the commence-
ment of study are usually excluded.
Mosholder et al.21 reviewed data on hallucinations and other
psychotic symptoms associated with the use of ADHD drugs
(included MPH, modaﬁnil, dextromethylphenidate, amphetamine
and atomoxetine) from 49 randomised controlled clinical trials.
Although the aggregated adverse-event data found that a rate of
psychosis/mania event was 1.48 per 100 person-years in ADHD
treatment group, only four events were reported in trials for MPH
products; all were from transdermal patch treatment only and
none for oral MPH products. In HK, only oral MPH products are
available.
A recent study in Canada recruited a group of parents with
severe mental illness and used questionnaires to investigate the
relationship between stimulant medication use and psychotic
symptoms.43 The authors identiﬁed 24 patients who had been
exposed to stimulants in lifetime. Among them, 15 had lifetime
occurrence of psychotic and related symptoms with adjusted odds
ratio of 4.41 when comparing with individuals who had never
used stimulants. This study included a group of high-risk
individuals with psychiatric family history which, as stated by
the authors, were unable to test whether family history moderates
the risk of psychotic symptoms.43 In addition, the temporal
relationship of psychotic symptoms identiﬁed and reported use of
stimulants were not known in this study. Thus, the ﬁndings only
showed an association but do not prove causality. We found an
IRR of 4.64 before the initiation of MPH treatment that was
comparable to the odds ratio in this Canadian study. Therefore,
our study results raised the possibility of reverse causality between
MPH use and psychotic disorders.
Another recent cohort study in Taiwan24 investigated the
association between MPH and schizophrenia spectrum disorders,
and concluded that there was an increased risk of psychotic
disorder in ADHD patients taking MPH compared with non-users
(adjusted hazard ratio = 1.20). However, our data ﬁnd a lower and
not statistically different estimate (IRR = 1.02). The discrepancy
between the results may be explained by differences in study
design. We applied the SCCS design, which controls for the effects
of unmeasured confounders more robustly, as the within-person
study design controls implicitly for confounders that do not vary
over time.36 In the Taiwanese study, as acknowledged by the
authors, several potential confounders remained unmeasured.
These included the baseline severity of ADHD symptoms, and
family history of psychosis, both of which may affect the results of
a cohort study. These potential confounders, even though they
were not captured in our database, should not have an impact on
the ﬁndings reported here using the SCCS design. This may
explain why our study resulted in an estimate closer to 1.
Although the SCCS design was able to control confounders that
do not vary over time, it may not be able to control for changes in
ADHD severity. ADHD severity may change over time, which is
likely to be associated with MPH treatment and is potentially a risk
factor for psychotic symptoms. This bias would likely result in an
overestimation of the true risk of association, as patients with
more severe ADHD are more likely to be treated as well as being
at higher risk for psychotic events. Therefore, even if this was the
case, it is unlikely to change the direction of our conclusions.
There are a number of limitations in our study. First, CDARS
does not have linkage to data from private medical practitioners.
Therefore, we were not able to include prescriptions from the
private sector, which may potentially lead to exposure misclassi-
ﬁcation. However, in HK, the public sector is the main provider of
specialist care46 and there are very few private child and
Table 3. Results from the self-controlled case series analyses
IRR 95% CI P-value
Incident psychotic episode (n = 103)
Period with MPH treatment 0.98 0.52–1.86 0.95
Pre-risk period included
90 Days before ﬁrst MPH treatment 4.64 2.17–9.92 o0.01
Period with MPH treatment 1.02 0.53–1.97 0.95
Sensitivity analyses
6-Month age band (n= 103)
90 Days before ﬁrst MPH treatment 3.91 1.85–8.28 o0.01
Period with MPH treatment 0.84 0.46–1.55 0.58
Patients with 410 weeks' MPH
exposure (n= 82)
90 Days before ﬁrst MPH treatment 4.38 1.77–10.87 o0.01
Period with MPH treatment 1.07 0.55–2.08 0.85
Censor by antidepressants/
antipsychotics (n= 102)
90 Days before ﬁrst MPH treatment 6.67 2.84–15.66 o0.01
Period with MPH treatment 0.92 0.40–2.13 0.84
Remove patients with substance
dependence (n= 87)
90 Days before ﬁrst MPH treatment 5.01 2.32–10.81 o0.01
Period with MPH treatment 0.89 0.44–1.78 0.74
Remove hallucination cases (n= 83)
90 Days before ﬁrst MPH treatment 3.37 1.22–9.32 0.02
Period with MPH treatment 1.11 0.53–2.31 0.79
Remove cases with event on the ﬁrst
day of treatment (n= 102)
90 Days before ﬁrst MPH treatment 4.04 1.82–8.95 o0.01
Period with MPH treatment 0.99 0.51–1.92 0.66
Washout period: 7 days before the ﬁrst
treatment (n= 90)
90 Days before ﬁrst MPH treatment 3.90 1.69–9.01 o0.01
Period with MPH treatment 1.01 0.53–1.94 0.97
Washout period: 14 days before the
ﬁrst treatment (n= 90)
90 Days before ﬁrst MPH treatment 4.26 1.84–9.86 o0.01
Period with MPH treatment 1.01 0.53–1.94 0.98
Washout period: 21 days before the
ﬁrst treatment (n= 89)
90 Days before ﬁrst MPH treatment 3.96 1.62–9.69 o0.01
Period with MPH treatment 1.01 0.53–1.95 0.97
Start of observation at 1 January 2001,
the sixth birthday of the patient, the
ﬁrst observed date of ADHD diagnosis
or the ﬁrst date of MPH treatment,
whichever occurred last (n= 79)
90 Days before ﬁrst MPH treatment 3.59 1.13–11.4 o0.01
Period with MPH treatment 1.26 0.61–2.59 0.53
60-Day pre-exposure period
60 Days before ﬁrst MPH treatment 5.99 2.71–13.22 o0.01
Period with MPH treatment 1.01 0.53–1.95 0.97
30-Day pre-exposure period
30 Days before ﬁrst MPH treatment 5.21 1.83–14.81 o0.01
Period with MPH treatment 0.94 0.49–1.81 0.86
Abbreviations: 95% CI, 95% lower conﬁdence interval of IRR; ADHD,
attention deﬁcit/hyperactivity disorder; IRR, adjusted incidence rate ratio;
MPH, methylphenidate.
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adolescent psychiatrists.14,47 As a consequence, patients who
require long-term care, such as those with neurodevelopmental
disorders and ADHD, are generally treated in the public health-
care sector,14 and the vast majority should have been included in
this study. In addition, our cohort only included clinically referred
patients who had sufﬁciently severe ADHD symptoms and/or
impairment to be prescribed MPH treatment. Therefore, our
cohort may have a higher baseline risk than non-medicated
patients. However, as the aim of the study was to evaluate the
effect of MPH on the risk of a psychotic event, our cohort included
all patients with MPH treatment within the public health-care
system. Hence, our cohort is highly representative. Furthermore, as
we applied a SCCS design, individual baseline risk will not affect
our study results and conclusion. Second, similar to other
pharmacoepidemiological studies using automated databases,
CDARS provides the data on drug prescription, but not on
adherence (compliance) to medication, and this may lead to
misclassiﬁcation of exposure periods. However, these potential
limitations due to non-compliance with medication were
addressed to some extent in the sensitivity analysis, and the
results remained similar. Third, despite having identiﬁed that in
95.1% cases, the diagnoses of a psychotic event was conﬁrmed by
a hospital paediatrician and/or a psychiatrist, we cannot rule out
the possibility of under-diagnosis in which the sensitivity of
diagnosis may depend on treatment status. For example,
physician visits may be more frequent during periods with MPH
treatment, and therefore diagnosis of psychotic events/hallucina-
tions more likely to come to clinical attention and diagnosis. This
differential under-diagnosis may potentially lead to an over-
estimation in the IRR during treatment. However, this again would
be unlikely to affect the study conclusions. Fourth, the upper limit
of CI for the reported IRR during MPH treatment is just below 2; we
cannot exclude the possibility of the risk of incident psychotic
events doubling during treatment as we do not have sufﬁcient
statistical power to detect an IRR below 2. However, even if there
is an increased risk, the absolute increased risk would be small, as
the absolute risk of incident psychotic events was 1 per 1629
patient-years. More importantly, the IRR is statistically signiﬁcantly
lower during MPH treatment than for the pre-treatment period;
therefore, there is no evidence to support an increased risk
associated with the MPH treatment. Fifth, we cannot evaluate the
deterioration, persistence or recurrence of the psychotic disorders
after the incident diagnosis date. In particular, for patients with
schizophrenia, we are unable to determine the risk of deteriora-
tion, owing to insufﬁcient sample size. Further study should be
conducted to evaluate the risk of deterioration, persistence or
recurrence of psychotic symptoms in patients with a previous
history of psychotic events before the initiation of the MPH
treatment. Sixth, as we had a comparatively long follow-up time,
other time-varying confounding factors may affect our study
results. We hypothesised that the use of other psychiatric
medications may affect the association between MPH and
psychotic events. Therefore, we conducted a sensitivity analysis
by censoring patient-time after the ﬁrst antidepressant or
antipsychotic prescription, and the results were consistent with
our initial ﬁndings. Lastly, although there is no evidence to
suggest that Chinese patients respond differently to MPH than
other populations, we cannot fully exclude this as a possibility.
CONCLUSIONS
This study does not support the hypothesis that MPH increases
risk of incident psychotic events. It does, however, indicate an
increased risk of such events before the ﬁrst prescription of MPH,
which may be due to the association between psychotic events
and the behavioural and attention symptoms that led to
psychiatric consultations and initiation of treatment with MPH.
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